TaperCommunitydesvenlafaxine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Desvenlafaxine is the active metabolite of venlafaxine, formulated as an extended-release SNRI for major depressive disorder. It was designed to provide more predictable pharmacokinetics by bypassing CYP2D6 metabolism.
25mg, 50mg, 100mg
Extended-release tablets: 25mg, 50mg, 100mg
Category C (risk cannot be ruled out)
Serotonin-norepinephrine reuptake inhibitor (SNRI). Inhibits both the serotonin and norepinephrine transporters. Unlike its parent compound venlafaxine, it does not require CYP2D6 activation.
Extended-release tablets cannot be split. Compounding pharmacy needed for doses between available strengths.
Tablets cannot be crushed/split. Compounding pharmacy essential for fine reductions.
Toxicity
Serotonin syndrome with serotonergic combinations. Sustained hypertension. Lipid elevations reported. Severe discontinuation syndrome similar to venlafaxine.
Pristiq (desvenlafaxine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Neutral, high-authority entity references.
Primary literature cited in this taper guide.
Evidence-based deprescribing and prescribing standards.
Clinician-facing references on tapering protocols.
Long-running communities documenting withdrawal experience.
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.
Pharmacokinetics
Bioavailability ~80%. Tmax ~7.5 hours. Food does not significantly affect pharmacokinetics.
~3.4 L/kg
Hepatic conjugation (UGT) and to a minor extent CYP3A4-mediated oxidation. Does not rely on CYP2D6 for activation.
Renal (~45% unchanged, ~24% as glucuronide conjugate). Total urinary recovery ~~70%.
~30%
~215 mL/min (total body clearance)
Browse our map of deprescribing-informed providers worldwide.